Institut Pasteur

Other

Centre National De La Recherche Scientifique

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Agence Nationale De Valorisation De La Recherche (anvar)

Institut National De La Recherche Scientifique

Cabinet Harle & Phelip

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

Agence Nationale De Valorisation De La Recherche

Institut Pasteur and Centre National De La Recherche Scientifique

Urrma R & D

Urrma Biopharma

Jean-Claude Chermann

Luc Montagnier

Solange Chamaret

Francoise Barre-Sinoussi

Francoise Rey

Willy Rozenbaum

Christine Rouzioux

Claudine Axler-Blin

Charles Dauguet

Jacqueline Gruest

Robert C Gallo

Mikulas Popovic

Marie-Therese Nugeyre

Pierre Sonigo

Marc Alizon

Simon Wain-Hobson

Mangalasseril G Sarngadharan

Pierre Tiollais

Francoise Brun-Vezinet

Stewart T Cole

Bernard Krust

Francoise Barre Sinoussi

Emile R Bisagni

Francoise Wendling

Marie-Theresa Nugeyre

Claire Ducrocq

Jacques Gruest, Legal Representative

Francois Brun-Vezinet

Francois Clavel

Oliver Danos

Cole Stewart

Christian Rivalle

Pierre Tambourin

Olivier Danos

Fran&ccedil;ois Clavel

François Clavel

Francoise Vezinet-Brun

Francedillaois Clavel

Georges Mathe

Odette J Raynaud, Heir

Dominique Dormont

Marcel Raynaud, Deceased

Bruno Spire

Etienne Vilmer

Claude Jasmin

Francoise Vezinet-Bruil

Rosette Lidereau

Alain Civier

Francedillaoise Barre-Sinoussi

Blandine Rouquette

Mangalasseril G Sarngadhar

G Sarngadharan

Fran&ccedil;oise Barre-Sinoussi

Luc Montangnier

Camille Haslin

Ricardo De Oliveira

Francoise Barre

Françoise Barre-Sinoussi

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA, or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them, and the proteins expressed.

Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method of detecting lymphadenopathy associated virus or related viruses or DNA pro-viruses with cloned DNA sequences which are hybridizable to genomic RNA and DNA of lymphadenopathy associated virus. It further relates to the cloned DNA sequences and a process for their preparation.

Cloned DNA sequences hybridizable with genomic RNA of lymphadenopathy associated virus (LAV)

The inventors have isolated cloned cDNA encoding the RNA genome of Human Immunodeficiency Virus type 1 (HIV-1). Various clones are described, which encode different regions of the genome, including those regions encoding viral antigens or proteins. Hybridization results indicate the difference between the HIV-1 clones and those of HTLV-I and HTLV-II. The inventors have also produced a restriction map of the entire cloned genomic sequence in order to facilitate further subcloning and using the restriction fragments in other hybridization tests and in methods to express encoded sequences.

HIV-1 DNA fragments that hybridize to genomic HIV-1DNA

Method for detecting human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity

The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic tool, or as a preventive and curative medicament. The invention also relates to corresponding in vitro diagnostic methods.

Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)

This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA

This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.

Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1

The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.

Methods for the propagation, isolation, identification, and preparation of human immunodeficiency virus type 1 (HIV-1)

Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.

Antibody directed against HIV-1 P25 antigen

The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and various hydrophilic peptides obtained therefrom. These peptides correspond to amino acids 551-577, 594-603, 621-630, 657-679, and 719-758 of the LAV envelope glycoprotein. These peptides should provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.

Nucleic acids and peptides of human immunodeficiency virus type (HIV-1)

Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.

Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies

The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.

Methods and kits for detecting antibodies against an HIV variant

This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.

Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).

Growing community of inventors

Cassis, France

Jean-Claude Chermann